PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study.

Abstract The efficacy and safety of direct-acting antivirals (DAAs) for treating hepatitis C virus (HCV)-infected renal transplant recipients (RTRs) has not been determined.
PMID
Related Publications

Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.

Aminoadamantanes for chronic hepatitis C.

Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.

Direct-acting antivirals for chronic hepatitis C.

Nitazoxanide for chronic hepatitis C.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28746204
OWN - NLM
STAT- In-Process
DA  - 20170726
LR  - 20170726
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 30
DP  - 2017 Jul
TI  - Direct-acting antiviral agent efficacy and safety in renal transplant recipients 
      with chronic hepatitis C virus infection: A PRISMA-compliant study.
PG  - e7568
LID - 10.1097/MD.0000000000007568 [doi]
AB  - BACKGROUND: The efficacy and safety of direct-acting antivirals (DAAs) for
      treating hepatitis C virus (HCV)-infected renal transplant recipients (RTRs) has 
      not been determined. METHODS: We searched PubMed, Embase, and the Cochrane
      Central Register of Controlled Trials and assessed the quality of eligible
      studies using the Joanna Briggs Institute scale. DAA efficacy and safety were
      assessed using standard mean difference (SMD) with 95% confidence intervals
      (95%CIs). RESULTS: Six studies (360 RTRs) were included. Two hundred thirty six
      RTRs (98.3%) achieved sustained virological response within 12 weeks; HCV
      infection was cleared in 239 RTRs after 24-week treatment. Liver function
      differed significantly pre- and posttreatment (alanine aminotransferase, SMD:
      0.96, 95%CIs: 0.65, 1.26; aspartate aminotransferase, SMD: 0.89, 95%CIs: 0.60,
      1.18); allograft function pre- and posttreatment was not statistically different 
      (serum creatinine, SMD: -0.13, 95%CIs: -0.38, 0.12; estimated glomerular
      filtration rate, SMD: 0.20, 95%CIs: -0.11, 0.51). General symptoms (fatigue
      nausea dizziness or headache) were the most common adverse events (AEs) (39.3%). 
      Severe AEs, that is, anemia, portal vein thrombosis, and streptococcus
      bacteraemia and pneumonia, were present in 1.1%, 0.6%, and 1.1% of RTRs,
      respectively. CONCLUSION: Our findings suggest that DAAs are highly efficacious
      and safe for treating HCV-infected RTRs and without significant AE.
FAU - Chen, Keliang
AU  - Chen K
AD  - Department of Urology, First Affiliated Hospital with Nanjing Medical University,
      Nanjing, China.
FAU - Lu, Pei
AU  - Lu P
FAU - Song, Rijin
AU  - Song R
FAU - Zhang, Jiexiu
AU  - Zhang J
FAU - Tao, Rongzhen
AU  - Tao R
FAU - Wang, Zijie
AU  - Wang Z
FAU - Zhang, Wei
AU  - Zhang W
FAU - Gu, Min
AU  - Gu M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
EDAT- 2017/07/27 06:00
MHDA- 2017/07/27 06:00
CRDT- 2017/07/27 06:00
AID - 10.1097/MD.0000000000007568 [doi]
AID - 00005792-201707280-00035 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(30):e7568. doi: 10.1097/MD.0000000000007568.